NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response

Vaccine

Volumn 31, Issue 47, 2013, Pages 5549-5556

  Ibrahim, Ashraf S ^a,b   Luo, Guanpingsheng ^a   Gebremariam, Teclegiorgis ^a   Lee, Hongkyu ^a   Schmidt, Clint S ^c   Hennessey, John P ^c   French, Samuel W ^b,d   Yeaman, Michael R ^a,b,e   Filler, Scott G ^a,b   Edwards, John E ^a,b  

^a St John's Cardiovascular Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NovaDigm Therapeutics Inc   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Als3; Candida albicans; Murine; NDV 3; VVC

Indexed keywords

ALUMINUM HYDROXIDE; CANDIDA ALBICANS VACCINE; CYTOKINE; FUNGAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; NDV 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VAGINA CANDIDIASIS; VULVOVAGINAL DISEASE;

ALS3; CANDIDA ALBICANS; MURINE; NDV-3; VVC;

ANIMALS; B-LYMPHOCYTES; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; FEMALE; FUNGAL PROTEINS; FUNGAL VACCINES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; SERUM; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VAGINA;

EID: 84886799653     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.016     Document Type: Article

References (45)

1. Sobel J.D., Hasegawa A., Debernardis F., Adriani D., Pellegrini G., Cassone A., et al. Selected animal models: vaginal candidosis, Pneumocystis pneumonia, dermatophytosis and trichosporosis. Med Mycol 1998, 36(Suppl. 1):129-136.
2. Fidel P.L., Sobel J.D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Contracept Fertil Sex 1996, 24(January (1)):33-40.
3. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351(August (9)):876-883.
4. Bauters T.G., Dhont M.A., Temmerman M.I., Nelis H.J. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002, 187(September (3)):569-574.
5. Cernicka J., Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006, 27(May (5)):403-408.
6. Eckert L.O. Clinical practice. Acute vulvovaginitis. N Engl J Med 2006, 355(September (12)):1244-1252.
7. Pinjon E., Jackson C.J., Kelly S.L., Sanglard D., Moran G., Coleman D.C., et al. Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression. Antimicrob Agents Chemother 2005, 49(April (4)):1312-1318.
8. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43(May (5)):2155-2162.
9. Ventolini G., Baggish M.S., Walsh P.M. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med 2006, 51(June (6)):475-478.
10. Sheppard D.C., Yeaman M.R., Welch W.H., Phan Q.T., Fu Y., Ibrahim A.S., et al. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 2004, 279(July (29)):30480-30489.
11. Zhao X., Oh S.H., Cheng G., Green C.B., Nuessen J.A., Yeater K., et al. ALS3 and ALS8 represent a single locus that encodes a Candida albicans adhesin; functional comparisons between Als3p and Als1p. Microbiology 2004, 150(July (Pt 7)):2415-2428.
12. Nobile C.J., Mitchell A.P. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006, 8(September (9)):1382-1391.
13. Phan Q.T., Myers C.L., Fu Y., Sheppard D.C., Yeaman M.R., Welch W.H., et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007, 5(March (3)):e64.
14. Almeida R.S., Brunke S., Albrecht A., Thewes S., Laue M., Edwards J.E., et al. The hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog 2008, 4(November (11)):e1000217.
15. Spellberg B.J., Ibrahim A.S., Avanesian V., Fu Y., Myers C., Phan Q.T., et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006, 194(July (2)):256-260.
16. Ibrahim A.S., Spellberg B.J., Avenissian V., Fu Y., Filler S.G., Edwards J.E. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005, 73(February (2)):999-1005.
17. Spellberg B., Ibrahim A.S., Lin L., Avanesian V., Fu Y., Lipke P., et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008, 197(April (7)):967-971.
18. Lin L., Ibrahim A.S., Xu X., Farber J.M., Avanesian V., Baquir B., et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009, 5(December (12)):e1000703.
19. Lin L., Ibrahim A.S., Baquir B., Avanesian V., Fu Y., Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol 2009, 55(April (3)):293-295.
20. Conti HR, Gaffen SL. Host responses to Candida albicans: Th17 cells and mucosal candidiasis. Microbes Infect Jul;12(7):2010, 518-27.
21. van de Veerdonk FL, Kullberg BJ, Netea MG. Pathogenesis of invasive candidiasis. Curr Opin Crit Care October;16(5):2010, 453-9.
22. van de Veerdonk FL, Netea MG. T-cell subsets and antifungal host defenses. Curr Fungal Infect Rep December;4(4):238-43.
23. Yano J., Noverr M.C., Fidel P.L. Cytokines in the host response to Candida vaginitis: identifying a role for non-classical immune mediators, S100 alarmins. Cytokine 2012, 58(April (1)):118-128.
24. Chow Y.H., Chiang B.L., Lee Y.L., Chi W.K., Lin W.C., Chen Y.T., et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998, 160(February (3)):1320-1329.
25. Daley J.M., Thomay A.A., Connolly M.D., Reichner J.S., Albina J.E. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008, 83(January (1)):64-70.
26. Luo G., Gebremariam T., Lee H., French S.W., Wiederhold N.P., Patterson T.F., et al. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother 2013, 57(7):3340-3347.
27. Gukovsky I., Lugea A., Shahsahebi M., Cheng J.H., Hong P.P., Jung Y.J., et al. A rat model reproducing key pathological responses of alcoholic chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008, 294(January (1)):G68-G79.
28. Tsuchimori N., Sharkey L.L., Fonzi W.A., French S.W., Edwards J.E., Filler S.G. Reduced virulence of HWP1-deficient mutants of Candida albicans and their interactions with host cells. Infect Immun 2000, 68(April (4)):1997-2002.
29. Rahman D., Mistry M., Thavaraj S., Challacombe S.J., Naglik J.R. Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions. Microbes Infect 2007, 9(April (5)):615-622.
30. McClellan S.A., Huang X., Barrett R.P., van Rooijen N., Hazlett L.D. Macrophages restrict Pseudomonas aeruginosa growth, regulate polymorphonuclear neutrophil influx, and balance pro- and anti-inflammatory cytokines in BALB/c mice. J Immunol 2003, 170(May (10)):5219-5227.
31. Ismail H.F., Fick P., Zhang J., Lynch R.G., Berg D.J. Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J Immunol 2003, 170(April (7)):3782-3789.
32. Schmidt C.S., White C.J., Ibrahim A.S., Filler S.G., Fu Y., Yeaman M.R., et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012, 30(52):7594-7600.
33. Sobel J.D., Faro S., Force R.W., Foxman B., Ledger W.J., Nyirjesy P.R., et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998, 178(February (2)):203-211.
34. Parish C.R. Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity. J Exp Med 1971, 134(July (1)):21-47.
35. Parish C.R. Immune response to chemically modified flagellin. I. Induction of antibody tolerance to flagellin by acetoacetylated derivatives of the protein. J Exp Med 1971, 134(July (1)):1-20.
36. Parish C.R., Liew F.Y. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med 1972, 135(February (2)):298-311.
37. De Bernardis F., Boccanera M., Adriani D., Spreghini E., Santoni G., Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997, 65(August (8)):3399-3405.
38. Han Y., Morrison R.P., Cutler J.E. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998, 66(December (12)):5771-5776.
39. Jacquot S., Macon-Lemaitre L., Paris E., Kobata T., Tanaka Y., Morimoto C., et al. B cell co-receptors regulating T cell-dependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immuno-compromised patients. Int Immunol 2001, 13(July (7)):871-876.
40. Spellberg B., Edwards J.E. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001, 32(January (1)):76-102.
41. Fidel P.L., Luo W., Steele C., Chabain J., Baker M., Wormley F. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999, 67(June (6)):3135-3140.
42. Fidel P.L., Barousse M., Espinosa T., Ficarra M., Sturtevant J., Martin D.H., et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004, 72(May (5)):2939-2946.
43. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009, 206(February (2)):299-311.
44. Hernandez-Santos N, Huppler AR, Peterson AC, Khader SA, McKenna KC, Gaffen SL. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol 6 (September (5)), 2013, 900-910.
45. Yano J, Kolls JK, Happel KI, Wormley F, Wozniak KL, Fidel PL, Jr., The acute neutrophil response mediated by S100 alarmins during vaginal Candida infections is independent of the Th17-pathway. PLoS One;7(9):e46311.